Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Hosted on MSN8h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
ST. CLAIR COUNTY, Ill. – One person was left injured Wednesday morning after a vehicle was partially trapped underneath a ...
Steven Matregrano dives into the history of the Blizzard of '78, a storm that stranded thousands, claimed nearly 100 lives, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback